9-Me-BC (9-Methyl-β-carboline)

What Is 9-Me-BC?

9-Me-BC (9-methyl-β-carboline) is a small β-carboline alkaloid studied as a research compound for its effects on dopaminergic neurons. It is discussed informally as a nootropic aimed at dopamine and neurotrophic support, but its evidence base is entirely preclinical — rodent Parkinson’s-disease models and cultured-cell work. There are no human clinical trials, and it is not an approved medicine or dietary supplement. Any human “dopamine” or cognitive claim is extrapolated from animal and in-vitro data, not tested in people.

Evidence

In an animal (rodent) model of Parkinson’s disease, 9-me-BC restored tyrosine-hydroxylase-positive cell counts in the substantia nigra toward normal values after a dopaminergic lesion ^{1Reference 1Wernicke et al. · 2010AnimalWernicke, C., et al. (2010). 9-Methyl-β-carboline has restorative effects in an animal model of Parkinson’s disease — rat/in vivo. Journal of Neural Transmission. https://pubmed.ncbi.nlm.nih.gov/20360614/View study →}. In primary mesencephalic cell culture it increased the appearance of differentiated dopaminergic neurons and up-regulated a range of neurotrophic and transcription factors involved in dopaminergic differentiation ^{2Reference 2Hamann et al. · 2008In vitroHamann, J., et al. (2008). 9-Methyl-β-carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic culture — in vitro. Journal of Neurochemistry. https://pubmed.ncbi.nlm.nih.gov/17913302/View study →}. Further in-vitro work reported that 9-me-BC inhibits monoamine oxidase activity and stimulates astrocytic expression of neurotrophic factors such as BDNF ^{3Reference 3Gille et al. · 2020In vitroGille, G., et al. (2020). 9-Methyl-β-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytes — in vitro. Journal of Neural Transmission. https://pubmed.ncbi.nlm.nih.gov/32285253/View study →}. This is a coherent preclinical picture of stimulatory, neuroprotective and neurotrophic activity in dopaminergic systems — but all of it is animal/cell-culture data. No efficacy, dose or safety conclusion for humans follows, and I found no human study in this pass.

Dosage & Safety

There is no established human dose; circulating figures come from rodent studies, not clinical work, so none is given here. Human safety, toxicity and use in pregnancy are uncharacterised. One concrete pharmacological flag: β-carbolines, including 9-me-BC, can inhibit monoamine oxidase ^{3Reference 3Gille et al. · 2020In vitroGille, G., et al. (2020). 9-Methyl-β-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytes — in vitro. Journal of Neural Transmission. https://pubmed.ncbi.nlm.nih.gov/32285253/View study →}, which in principle raises interaction concerns with serotonergic drugs, other MAO inhibitors, and tyramine-rich foods — this has not been assessed in humans and is noted as a mechanistic caution, not a measured risk. 9-Me-BC is a research chemical, not an approved supplement or drug; this entry is informational only. Toxicity has not been characterised.

References

1. Wernicke, C., et al. (2010). 9-Methyl-β-carboline has restorative effects in an animal model of Parkinson’s disease — rat/in vivo. Journal of Neural Transmission. https://pubmed.ncbi.nlm.nih.gov/20360614/
2. Hamann, J., et al. (2008). 9-Methyl-β-carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic culture — in vitro. Journal of Neurochemistry. https://pubmed.ncbi.nlm.nih.gov/17913302/
3. Gille, G., et al. (2020). 9-Methyl-β-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytes — in vitro. Journal of Neural Transmission. https://pubmed.ncbi.nlm.nih.gov/32285253/